Inhalation Sedatives Global Market Report 2020: COVID-19 Impacts, Growth and Changes to 2030 –

Inhalation Sedatives Global Market Report 2020: COVID-19 Impacts, Growth and Changes to 2030 –

Inhalation Sedatives Global Market Report 2020: COVID-19 Impacts, Growth and Changes to 2030 –

DUBLIN–(BUSINESS WIRE)–The “Inhalation Sedatives Global Market Report 2020-30: COVID-19 Growth and Change” report has been added to’s offering.

The global inhalation sedatives market is expected to increase from $1.27 billion in 2019 to $1.29 billion in 2020 at a compound annual growth rate (CAGR) of 1.2%.

The growth is mainly due to the COVID-19 outbreak. The infected individuals with severe ARDS require sedation most frequently, and inhalation sedatives are being increasingly considered as they are associated with rapid onset of inhalation and effective outcomes. Inhaled sedatives can reduce lung inflammation, shorten the duration of ventilation and potentially improve survival.

The market is then expected to stabilize and reach $1.48 billion in 2023 at a CAGR of 4.8%.

Major players in the inhalation sedatives market are AbbVie Inc., Baxter International Inc., Fresenius SE amp; Co. KgaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC., Jiangsu Hengrui Medicine Co, Lunan Pharmaceutical Group Co. Ltd, Novartis AG, Piramal Enterprises Ltd and Troikaa Pharmaceuticals Ltd.

The inhalation sedatives market consists of sales of inhalation sedatives by companies who manufacture them. Inhalation sedatives are the drugs used to induce or maintain inhalation sedation, which is a type of conscious sedation where a drug is inhaled to suppress the central nervous system activity so that there is no much stress on the patient during a surgical process or a treatment and responds to the physician commands without protective reflexes. Inhalation sedatives are used in hospitals, ambulatory surgical centers and other care providing centers.

North America was the largest region in the inhalation sedatives market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

The production of generic inhalation sedatives is expected to be the new trend in the inhalation sedatives market. Generics are a type of drug that has the same chemical formula, dosage form, dose and effect as that of the patented drug but are produced by the companies when the patent expires. The generic inhalation sedatives production has increased for the last few years. Therefore, the production of generic inhalation sedatives is expected to become the new trend in the inhalation sedatives market.

The inhalation sedatives market covered in this report is segmented by product into sevoflurane; desflurane; isoflurane; nitrous oxide. It is also segmented by application into induction; maintenance and by end-user into hospitals; ambulatory surgical centers; others.

The short onset and duration time of inhalation sedative is expected to drive the inhalation sedative market. Rapid onset of inhalation sedative and quick recovery rate makes it applicable for short procedures especially in dental surgeries of paediatrics, and in intensive care units for decreasing the pain and quick recovery.

Market Scope

Markets Covered:

1) By Product: Sevoflurane; Desflurane; Isoflurane; Nitrous Oxide

2) By Application: Induction; Maintenance

3) By End-User: Hospitals; Ambulatory Surgical Centers; Others

Companies Featured: AbbVie Inc.; Baxter International Inc.; Fresenius SE & Co. KgaA; Halocarbon Products Corporation; Hikma Pharmaceuticals PLC.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Companies Mentioned

  • AbbVie Inc.
  • Baxter International Inc.
  • Fresenius SE & Co. KGaA
  • Halocarbon Products Corporation
  • Hikma Pharmaceuticals PLC.
  • Jiangsu Hengrui Medicine Co
  • Lunan Pharmaceutical Group Co. Ltd
  • Novartis AG
  • Piramal Enterprises Ltd
  • Troikaa Pharmaceuticals Ltd

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900